← Leaderboards
Maryam Banikazemi
Mount Sinai School Of Medicine Of Nyu
$439,377
Attributed
$439,377
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $129.8K · FY2005–07$200K$150K$100K$50K$0
'05
'06
'07
Funding mix
By agency
NIH$439,377 · 8
By mechanism
M01$439,377 · 8
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Robert F Margolskee$16,803,321
- Steven R Levine$10,462,040
- Melissa P Wasserstein$648,135
- Jonine Lisa Bernstein$38,646,945
- Margaret M McGovern$2,221,582
Others in their field
Top investigators on “Alpha Galactosidase”
- Cheryl Louise Stucky · Medical College Of Wisconsin$4,767,055
- Yu-Teh Li · Tulane University Of Louisiana$3,113,466
- Luc Teyton · Scripps Research Institute, The$2,916,161
- Ervin H Epstein · University Of California San Francisco$2,732,941
- Nancy M. Dahms · Medical College Of Wisconsin$2,662,492
- James Alan Shayman · University Of Michigan At Ann Arbor$2,450,889
Research focus
Alpha GalactosidaseDrug Screening /EvaluationHuman Therapy EvaluationClinical ResearchProtein EngineeringEnzyme TherapyHuman SubjectRecombinant ProteinsFabry'S DiseaseBiotechnologyMetabolism Disorder ChemotherapyClinical TrialsDosageVascular EndotheliumClinical Trial Phase IvCardiovascular DisorderClinical Trial Phase IiiEnrollmentClinical Trial Phase IiBiotherapeutic AgentEligibility DeterminationDrug Administration Rate /DurationChronic Disease /DisorderDesign
Grant awards (11)
PROTOCOL TO EVALUATE GAA ACTIVITY & GENE MUTATIONS IN LATE-ONSET POMPE DISEASE$1,216
M01 · FY2007 · RR · contact PI
STUDY OF THE SAFETY AND EFFICACY OF FABRAZYME IN PATIENTS WITH FABRY DISEASE$30,027
M01 · FY2006 · RR · contact PI
GAA ACTIVITY AND GENE MUTATIONS IN PATIENTS WITH LATE ONSET POMPE DISEASE$20,911
M01 · FY2006 · RR · contact PI
1 MG/KG BIWEEKLY FABRAZYME ON GASTROINTESTINAL SYMPTOMS OF FABRY DISEASE$9,651
M01 · FY2006 · RR · contact PI
MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF FABRAZYME IN PATI$102,672
M01 · FY2005 · RR
PHASE III EXTENSION PROTOCOL TO ASSESS THE SAFETY AND EFFICACY OF RECOMBINANT$27,178
M01 · FY2005 · RR
Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safet...$167,211
M01 · FY2004 · RR
Phase II, Randomized, Open-Label, Dose-Ranging, Multiple Dose Study of Fabraz...$30,345
M01 · FY2004 · RR
Phase III Extension Protocol to Assess the Safety and Efficacy of Recombinant...$27,250
M01 · FY2004 · RR
Multicenter, Open-Label Study of the Safety and Efficacy of Fabrazyme in pati...$12,387
M01 · FY2004 · RR
An Open Label Extension Study of Recombinant Human Alpha-Galactosidase Therap...$10,529
M01 · FY2004 · RR